

Curriculum vitae MAURO GIULIO PAPOTTI

Personal details

Born in **TORINO** on **July 5, 1955**

Nationality: **ITALIAN**

Email: mauro.papotti@unito.it

ORCID ID: **0000-0002-2713-1700**; Scopus ID: **7006493214**; Researcher ID: **CAJ-5629-2022**

Educations

- Medical doctor degree, cum laude (**University of Torino, 1980**)
- Postgraduate Specialization in Oncology (**University of Modena, 1983**)
- Postgraduate Specialization in Pathology (**University of Torino, 1991**).

Professional experiences

- 16.1.1982 - 1.11.1992:** consultant pathologist at the Azienda San Giovanni Battista Molinette (ex ASL TO 8, ex ASL 1-32), Corso Bramante 88, 10126 Torino
- 1.11.1992 - 30.9.2003:** associated professor and full professor of Pathology at the University of Torino and consultant pathologist at the Azienda San Giovanni Battista / Molinette
- 30.9.2003 - 14.6.15:** full professor of Pathology at the University of Torino and Head of Pathology division at the Azienda San Luigi Gonzaga, Regione Gonzole 10, 10043 Orbassano – Torino
- 1.11.11 - 14.6.15:** Acting Director of the Department of Health Services at the same Azienda San Luigi Gonzaga
- 15.6.15 – present:** full professor of Pathology at the University of Torino and Head of the Pathology Division at the Città della Salute hospital / Molinette, Torino

Current position: Full Professor of Pathology, University of Turin;
Head, Division of Pathology, Città della Salute Hospital and University of Torino,
Via Santena 7, 10126 Torino, Italy, Phone +390116705800

Participation to Directive Boards of Scientific Societies and/or Institutions

- Member of the International Academy of Pathology (IAP), European Society of Pathology (ESP), Società Italiana di Anatomia Patologica (SIAPEC), Endocrine Pathology Society, International Association for the Study of Lung Cancer (IASLC), European Neuroendocrine Tumor Society (ENETS), Pulmonary Pathology Society (PPS).
- Member of the Pathology Committee of the International Association for the study of lung cancer /IASLC (2019-present).
- Member of the US Pulmonary Pathology Society /PPS Scientific Committee (2019-2022)
- Invited member of the editorial boards for the WHO classification of tumors [Endocrine tumors; Thoracic tumors; Cytopathology books (Editions from 2004 to present)].
- Member of the Editorial Board of the following journals: Virchows Archives, Archives of Pathology, American Journal of Clinical Pathology, Journal of Pathology, J Clinical Pathology. Regular reviewer for numerous pathology journals in the past 25 years.
- Secretary (1990-1999) and President (2000- 2003) of the “European School of Pathology (ESCoP)”, founded in Torino by the European Society of Pathology (ESP).
- Within the University of Turin:** member of the Senato Accademico (2010-2012), member of the medical commission (2011-2021), vice-chair of the Medical School (2013-2021), member of the ECM commission (2013-present), member of the joint Regione Piemonte-University medical commission (2011-2018).

Diagnostic activity

1982-present: Diagnostic cytology (both exfoliative and fine needle aspiration biopsies); pulmonary & thoracic pathology; endocrine pathology. Application of immunohistochemistry and molecular techniques to histological and cytological specimens for diagnostic, prognostic and predictive purposes.

Teaching activity

Pathology courses at the University of Turin First Medical School in Turin (years 1992-2003 and from 2015-present) and Second Medical School in Orbassano (from 1997-2017). Pathology course at the Laboratory Technician School, University of Turin (1994-present). Cytopathology and surgical pathology courses at the Post-graduate Schools (Residents' programs) in Pathology, Oncology, Respiratory Medicine, Thoracic Surgery, Forensic medicine and Endocrinology (years 1987-present).

Research main topics

Thoracic pathology (lung and mesothelium), Endocrine pathology (parathyroid, thyroid and adrenal glands as well as neuroendocrine tumors) and immunohistochemical and molecular biology techniques applied to diagnostic pathology and aspiration biopsy cytology. Receptor analysis in endocrine tumors. Analysis of prognostic and predictive markers in endocrine and thoracic tumors.

Main projects as PI:

- Compagnia di San Paolo (2016): Novel integrated approaches in diagnostic pathology of rare tumors.
- Fondazione Berlucchi for cancer research (2013): Pathological analysis and molecular profiling of lung cancer biopsies to design and monitor systemic treatments
- AIRC, Milan: Pathological and molecular characterization of adrenal tumors (Grants years 2010, 2013, 2023)
- AIRC, Milan: Pathological and molecular characterization of thyroid tumors (grant year 2017)

Bibliometry (1982-present) (www.scopus.com)

H-index: 93; Citations: 31.178 from 593 documents (February 24, 2023)

10 best publications (with year 2022 Impact Factor)

1-Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubaatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A. Adjuvant mitotane treatment for adrenocortical carcinoma. *N Engl J Med.* 2007;356:2372-80. PMID: 17554118. **IF 91.0245**

2-Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, Inohara H, Marandino F, Orlandi F, Nardi F, Vecchione A, Tecce R, Larsson O; Thyroid Cancer Study Group. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. *Lancet.* 2001;357(9269):1644-50. PMID: 11425367. **IF 79.311**

3-Papotti M, Kalebic T, Volante M, Chiusa L, Bacillo E, Cappia S, Lausi P, Novello S, Borasio P, Scagliotti GV. Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study. *J Clin Oncol.* 2006;24:4818-24. PMID: 17050866. **IF 44.544**

4-Generali D, Buffa FM, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Papotti M, Dogliotti L, Bottini A, Harris AL, Fox SB. Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. *J Clin Oncol.* 2009;27:227-34. PMID: 19064988. **IF 44.544**

5-Righi L, Papotti MG, Ceppi P, Billè A, Bacillo E, Molinaro L, Ruffini E, Scagliotti GV, Selvaggi G. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. *J Clin Oncol.* 2010;28:1534-9. PMID: 20177021. **IF 44.544**

6-Bartolazzi A, Orlandi F, Saggiorato E, Volante M, Arecco F, Rossetto R, Palestini N, Ghigo E, Papotti M, Bussolati G, Martegani MP, Pantellini F, Carpi A, Giovagnoli MR, Monti S, Toscano V, Sciacchitano S, Pennelli GM, Mian C, Pelizzo MR, Rugge M, Troncone G, Palombini L, Chiappetta G, Botti G, Vecchione A, Bellocchio R; Italian Thyroid Cancer Study Group (ITCSG). Galectin-3-expression analysis in the surgical selection of follicular

thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. *Lancet Oncol.* 2008;9:543-9. PMID: 18495537. **IF 41.316**

7-Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, Barletta JA, Wenig BM, Al Ghuzlan A, Kakudo K, Giordano TJ, Alves VA, Khanafshar E, Asa SL, El-Naggar AK, Gooding WE, Hodak SP, Lloyd RV, Maytal G, Mete O, Nikiforova MN, Nosé V, Papotti M, Poller DN, Sadow PM, Tischler AS, Tuttle RM, Wall KB, LiVolsi VA, Randolph GW, Ghossein RA. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. *JAMA Oncol.* 2016;2:1023-9. PMID: 27078145; **IF 33.0**

8-Righi L, Volante M, Tavaglione V, Billè A, Daniele L, Angusti T, Inzani F, Pelosi G, Rindi G, Papotti M. Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. *Ann Oncol.* 2010;21:548-555. PMID: 19759190. **IF 32.976**

9-Boffetta P, Righi L, Ciocan C, Pelucchi C, La Vecchia C, Romano C, Papotti M, Pira E. Validation of the diagnosis of mesothelioma and BAP1 protein expression in a cohort of asbestos textile workers from Northern Italy. *Ann Oncol.* 2018;29:484-489. PMID: 29206890. **IF 32.976**

10-Filetti S, Durante C, Hartl DM, Leboulleux S, Locati LD, Newbold K, Papotti MG, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. *Ann Oncol.* 2022;33:674-684. PMID: 35491008. **IF 32.976**

15 more relevant publications in the last 5 years (2018-2022)

1: Invasion working group; Thunnissen E, Beasley MB, Borczuk A, Dacic S, Kerr KM, Minami Y, Nicholson AG, Sholl L, Tsao MS, Noguchi M, Lissenberg-Witte B, Le Quesne J, Roden AC, Chung JH, Yoshida A, Moreira AL, Lantuejoul S, Pelosi G, Poleri C, Hwang D, Jain D, Travis WD, Brambilla E, Chen G, Botling J, Bubendorf L, Mino-Kenudson M, Motoi N, Chou TY, Papotti M, Yatabe Y, Cooper W. Defining morphologic features of invasion in pulmonary non-mucinous adenocarcinoma with lepidic growth - A proposal by the IASLC Pathology Committee. *J Thorac Oncol.* 2022 Dec 8:S1556-0864(22)01936-0. PMID: 36503176.

2: Vaisitti T, Vitale N, Micillo M, Brandimarte L, Iannello A, Papotti MG, Jaksic O, Lopez G, Di Napoli A, Cutrin JC, Orlik C, Kulke M, Pahl A, Deaglio S. Anti-CD37 α-amanitin-conjugated antibodies as potential therapeutic weapons for Richter syndrome. *Blood.* 2022 Sep 29;140(13):1565-1569. PMID: 35914223.

3: Filetti S, Durante C, Hartl DM, Leboulleux S, Locati LD, Newbold K, Papotti MG, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. *Ann Oncol.* 2022 Jul;33(7):674-684. PMID: 35491008.

4: Jain D, Nambirajan A, Chen G, Geisinger K, Hiroshima K, Layfield L, Minami Y, Moreira AL, Motoi N, Papotti M, Rekhtman N, Russell PA, Prince SS, Schmitt F, Yatabe Y, Eppenberger-Castori S, Bubendorf L; IASLC Pathology Committee. NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma. *J Thorac Oncol.* 2022 Jun;17(6):793-805. PMID: 35331963.

5: Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, Dacic S, Jain D, Kerr KM, Lantuejoul S, Noguchi M, Papotti M, Rekhtman N, Scagliotti G, van Schil P, Sholl L, Yatabe Y, Yoshida A, Travis WD. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. *J Thorac Oncol.* 2022 Mar;17(3):362-387. PMID: 34808341.

6: Marx A, Chan JKC, Chalabreysse L, Dacic S, Detterbeck F, French CA, Hornick JL, Inagaki H, Jain D, Lazar AJ, Marino M, Marom EM, Moreira AL, Nicholson AG, Noguchi M, Nonaka D, Papotti MG, Porubsky S, Sholl LM, Tateyama H, Thomas de Montpréville V, Travis WD, Rajan A, Roden AC, Ströbel P. The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors? *J Thorac Oncol.* 2022 Feb;17(2):200-213. PMID: 34695605.

7: Metovic J, Falco EC, Vissio E, Santoro F, Delsedime L, Massa F, Pittaro A, Osella-Abate S, Cassoni P, Volante M, Righi L, Papotti M. Gross Specimen Handling Procedures Do Not Impact the Occurrence of Spread Through Air Spaces (STAS) in Lung Cancer. *Am J Surg Pathol.* 2021 Feb 1;45(2):215-222. PMID: 33323894.

8: Metovic J, Vignale C, Annaratone L, Osella-Abate S, Maletta F, Rapa I, Cabutti F, Patriarca S, Gallo M, Nikiforov YE, Volante M, Papotti M. The Oncocytic Variant of Poorly Differentiated Thyroid Carcinoma Shows a Specific Immune-Related Gene Expression Profile. *J Clin Endocrinol Metab.* 2020 Dec 1;105(12):e4577-92. PMID: 32936917.

- 9: Moreira AL, Ocampo PSS, Xia Y, Zhong H, Russell PA, Minami Y, Cooper WA, Yoshida A, Bubendorf L, Papotti M, Pelosi G, Lopez-Rios F, Kunitoki K, Ferrari-Light D, Sholl LM, Beasley MB, Borczuk A, Botling J, Brambilla E, Chen G, Chou TY, Chung JH, Dacic S, Jain D, Hirsch FR, Hwang D, Lantuejoul S, Lin D, Longshore JW, Motoi N, Noguchi M, Poleri C, Rekhtman N, Tsao MS, Thunnissen E, Travis WD, Yatabe Y, Roden AC, Daigneault JB, Wistuba II, Kerr KM, Pass H, Nicholson AG, Mino-Kenudson M. A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. *J Thorac Oncol.* 2020 Oct;15(10):1599-1610. PMID: 32562873.
- 10: Sholl LM, Hirsch FR, Hwang D, Botling J, Lopez-Rios F, Bubendorf L, Mino-Kenudson M, Roden AC, Beasley MB, Borczuk A, Brambilla E, Chen G, Chou TY, Chung JH, Cooper WA, Dacic S, Lantuejoul S, Jain D, Lin D, Minami Y, Moreira A, Nicholson AG, Noguchi M, Papotti M, Pelosi G, Poleri C, Rekhtman N, Tsao MS, Thunnissen E, Travis W, Yatabe Y, Yoshida A, Daigneault JB, Zehir A, Peters S, Wistuba II, Kerr KM, Longshore JW. The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. *J Thorac Oncol.* 2020 Sep;15(9):1409-1424. PMID: 32522712.
- 11: Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-RiosF, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. *J Thorac Oncol.* 2020 May;15(5):709-740. PMID: 32004713.
- 12: Alcalá N, Leblay N, Gabriel AAG, Mangiante L, Hervas D, Giffon T, Sertier AS, Ferrari A, Derkx J, Ghantous A, Delhomme TM, Chabrier A, Cuenin C, Abedi-Ardekani B, Boland A, Olaso R, Meyer V, Altmüller J, Le Calvez-Kelm F, Durand G, Voegele C, Boyault S, Moonen L, Lemaitre N, Lorimier P, Toffart AC, Soltermann A, Clement JH, Saenger J, Field JK, Brevet M, Blanc-Fournier C, Galateau-Salle F, Le Stang N, Russell PA, Wright G, Sozzi G, Pastorino U, Lacomme S, Vignaud JM, Hofman V, Hofman P, Brustugun OT, Lund-Iversen M, Thomas de Montpreville V, Muscarella LA, Graziano P, Popper H, Stojscic J, Deleuze JF, Herceg Z, Viali A, Nuernberg P, Pelosi G, Dingemans AMC, Milione M, Roz L, Brcic L, Volante M, Papotti MG, Caux C, Sandoval J, Hernandez-Vargas H, Brambilla E, Speel EJM, Girard N, Lantuejoul S, McKay JD, Foll M, Fernandez-Cuesta L. Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. *Nat Commun.* 2019 Aug 20;10(1):3407. PMID: 31431620.
- 13: Marchiò C, Da Cruz Paula A, Gularce-Merida R, Basili T, Brandes A, da Silva EM, Silveira C, Ferrando L, Metovic J, Maletta F, Annaratone L, Pareja F, Rubin BP, Hoschar AP, De Rosa G, La Rosa S, Bongiovanni M, Purgina B, Piana S, Volante M, Weigelt B, Reis-Filho JS, Papotti M. PAX8-GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid. *Mod Pathol.* 2019 Dec;32(12):1734-1743. PMID: 31273314.
- 14: Villanova T, Gesmundo I, Audrito V, Vitale N, Silvagno F, Musuraca C, Righi L, Libener R, Riganti C, Bironzo P, Deaglio S, Papotti M, Cai R, Sha W, Ghigo E, Schally AV, Granata R. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma. *Proc Natl Acad Sci USA.* 2019 Feb 5;116(6):2226-2231. PMID: 30659154.
- 15: Pelosi G, Papotti M, Righi L, Rossi G, Ferrero S, Bosari S, Calabrese F, Kern I, Maisonneuve P, Sonzogni A, Albini A, Harari S, Barbieri F, Capelletto E, Catino AM, Cavone D, De Palma A, Fusco N, Lunardi F, Maiorano E, Marzullo A, Novello S, Papanikolaou N, Pasello G, Pennella A, Pezzuto F, Punzi A, Prisciandaro E, Rea F, Rosso L, Scattone A, Serio G. Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal. *J Thorac Oncol.* 2018 Nov;13(11):1750-1761. PMID: 30249391.